{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-320242","form_type":"8-K","ticker":"TEVA","cik":"0000818686","company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","filed_at":"2021-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:15.694253+00:00","generated_at":"2026-06-28T13:30:01.216277+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Teva prices $5B equivalent sustainability-linked notes; proceeds to repay debt","bullets":["Teva upsized and priced €1.1B 3.75% notes due 2027, €1.5B 4.375% notes due 2030, $1B 4.75% notes due 2027, and $1B 5.125% notes due 2029.","Largest-ever sustainability-linked note offering and first by a generic medicine company; tied to access-to-medicines and GHG targets.","Net proceeds to fund tender offer for up to $3.5B of existing senior notes maturing 2022-2024 and for general corporate purposes.","Settlement expected November 9, 2021; notes are unsecured senior obligations guaranteed by Teva."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-320242","json":"https://secwatch.observer/filing/0001193125-21-320242.json","markdown":"https://secwatch.observer/filing/0001193125-21-320242.md","text":"https://secwatch.observer/filing/0001193125-21-320242.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818686/000119312521320242/0001193125-21-320242-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818686/000119312521320242/d599039d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T13:30:01.216277+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}